NICE rejects MS symptom-relieving treatments

NICE has rejected the NHS use of two treatments indicated to relieve certain symptoms of multiple sclerosis (MS).

People who are already receiving Sativex or Fampyra on the NHS should be able to continue treatment until they and their NHS clinician decide it is appropriate to stop.
People who are already receiving Sativex or Fampyra on the NHS should be able to continue treatment until they and their NHS clinician decide it is appropriate to stop.

In its updated clinical guideline on the management of MS in primary and secondary care, NICE advised that patients should not be offered the cannabis-derived oromucosal spray Sativex to treat spasticity or the oral treatment fampridine (Fampyra) to improve walking disability. NICE judged that neither option was cost-effective.

NICE has issued positive opinions on the oral MS treatments dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), and fingolimod (Gilenya) and parenteral alemtuzumab (Lemtrada).

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Fourth formoterol/budesonide dry powder inhaler launched

Fourth formoterol/budesonide dry powder inhaler launched

WockAIR is a further alternative to Symbicort Turbohaler.